Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression

Figure 1

Rosiglitazone (RSG) promoted the viability of MDCK cells. (a) MDCK cells were treated with a concentration gradient of RSG. (b) Cells were cotreated with various concentrations of RSG (0, 2, 4, 8, 16, 32, and 64 μmol/L) and oxalate (0.5 mM) in DMEM medium for 1, 2, and 4 h, and a CCK-8 assay was performed to assess cell viability. (c) The generation of ROS was detected by a DCFH-DA assay. (d) Percent of ROS overexpressing cells per group. (e) Viability of MDCK cells treated with RSG, oxalate, and PHA665752. The data shown are representative of at least three independent experiments. N: normal; G: GW9662; H: hour; PHA: PHA665752. , , and versus the control group; ^#, ^##, and ^### versus the 0.5 mM oxalate group; ^▽, ^▽▽, and ^▽▽▽ versus the RSG-treated group.

(a)

(b)

(c)

(d)

(e)